Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bone sarcomas are devastating primary bone cancers that mostly affect children, young adults, and the elderly. These aggressive tumors are associated with poor survival, and surgery remains the mainstay of treatment. Surgical planning is increasingly informed by positron emission tomography (PET), and tumor margin identification during surgery is aided by near-infrared fluorescence (NIRF) imaging, yet these investigations are confounded by probes that lack specificity for sarcoma biomarkers. We report the development of a dual-modal (PET/NIRF) immunoconjugate ([Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW) that targets MT1-MMP, a matrix metalloproteinase overexpressed in high-grade sarcomas. [Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW was synthesized site-specific chemoenzymatic glycan modification, characterized, and isolated in high specific activity and radiochemical purity. Saturation binding and immunoreactivity assays indicated only minor perturbation of binding properties. A novel mouse model of dedifferentiated chondrosarcoma based on intrafemoral inoculation of HT1080 WT or KO cells (high and low MT1-MMP expression, respectively) was used to evaluate target binding and biodistribution. Fluorescence and Cerenkov luminescence images of [Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW showed preferential uptake in HT1080 WT tumors. gamma counting revealed that uptake in MT1-MMP-positive tumors was significantly higher than that in control groups. Taken together, [Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW is a promising dual-modal sarcoma imaging agent for pre-operative surgical planning and intraoperative surgical guidance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389524 | PMC |
| http://dx.doi.org/10.1021/acs.bioconjchem.2c00306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vivo Evaluation of a Gallium-68-Labeled Tumor-Tracking Cyanine Dye for Positron Emission Tomography/Near-Infrared Fluorescence Carcinoma Imaging, Image-Guided Surgery, and Photothermal Therapy.
ACS Omega
February 2023
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China.
Article Synopsis
- The study introduces a new probe, IR808-DOTA, designed for dual-modal imaging (PET/NIRF) to enhance tumor diagnosis and surgical navigation.
- This probe improves on its predecessor, IR808, in water solubility and pharmacokinetics while maintaining similar tumor targeting and anticancer effects.
- When tested in mice, IR808-DOTA was effective for both tumor imaging and aiding in surgical navigation, significantly inhibiting tumor growth through direct cell destruction and promoting cancer cell death.
Synthesis and Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas.
Bioconjug Chem
August 2022
School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne NE1 7RU, U.K.
Article Synopsis
- * A new dual-modal imaging agent ([Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW) has been developed to target MT1-MMP, a protein often overexpressed in aggressive sarcomas, improving surgical planning and detection.
- * Testing in a mouse model demonstrated that this imaging agent showed higher accumulation in tumors with high MT1-MMP expression, suggesting its efficacy for better surgical guidance in treating sarcomas.
A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking.
Biomaterials
February 2021
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States. Electronic address:
Adoptive cell transfer of targeted chimeric antigen receptor (CAR) T cells has emerged as a highly promising cancer therapy. The pharmacodynamic action or CAR T cells is closely related to their pharmacokinetic profile; because of this as well as the risk of non-specific action, it is important to monitor their biodistribution and fate following infusion. To this end, we developed a dual-modal PET/near infrared fluorescent (NIRF) nanoparticle-based imaging agent for non-genomic labeling of human CAR T cells.
View Article and Find Full Text PDFA Conjugate of Pentamethine Cyanine and F as a Positron Emission Tomography/Near-Infrared Fluorescence Probe for Multimodality Tumor Imaging.
Int J Mol Sci
June 2017
Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medical College, 413 East 69th Street, New York, NY 10065, USA.
The novel synthesis of a dual-modality, pentamethine cyanine (Cy5) fluorescent, F positron emission tomography (PET) imaging probe is reported. The probe shows a large extinction coefficient and large quantum yield in the biologically transparent, near-infrared window (650-900 nm) for in vivo fluorescent imaging. This fluorophore bears the isotope, F, giving a F-PET/near-infrared fluorescent (NIRF), bi-modal imaging probe, that combines the long-term stability of NIRF and the unlimited penetration depth of PET imaging.
View Article and Find Full Text PDFSite-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
Proc Natl Acad Sci U S A
December 2015
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10075; Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10075;
Molecular imaging agents for preoperative positron emission tomography (PET) and near-infrared fluorescent (NIRF)-guided delineation of surgical margins could greatly enhance the diagnosis, staging, and resection of pancreatic cancer. PET and NIRF optical imaging offer complementary clinical applications, enabling the noninvasive whole-body imaging to localize disease and identification of tumor margins during surgery, respectively. We report the development of PET, NIRF, and dual-modal (PET/NIRF) imaging agents, using 5B1, a fully human monoclonal antibody that targets CA19.
View Article and Find Full Text PDF